McErlane, James http://orcid.org/0000-0002-0490-8425
McCall, Philip
Willder, Jennifer
Berry, Colin
Shelley, Ben
,
Reece, A.
Kitchen, C.
Gillies, M.
Dabek, V.
Irvine, V.
MacBrayne, J.
Sim, K.
Scott, T.
Trumper, E.
Savage, F.
Allan, A.
Falconer, J.
Coutts, A.
McDonald, A.
Rutherford, J.
Christie, D.
Jardine, C.
Puxty, A.
Hughes, M.
Cathcart, S.
Sim, M.
Docking, B.
Thornton, M.
Greatorex, B.
Rae, J.
Barr, C.
Bradley, C.
Barrett, F.
Campbell, R.
Clarke, N.
Mascarenhas, M.
Matheson, J.
McDonald, D.
O Hara, M.
O keeffe, L.
Gemmell, L.
Price, R.
McHendry, M.
McLaughlan, D.
Herman, C.
Elliot, H.
Meehan, S.
Allan, J.
Finn, D.
Brannan, G.
Wood, S.
Watson, T.
Ross, K.
Tatarkowska, N.
Boyle, R.
Lee, E.
Strachan, D.
Morrison, A.
Lucie, P.
Lochrin, C.
Clements, S.
Vigni, D.
Stanley, B.
Messow, C. M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Right ventricular free wall longitudinal strain is independently associated with mortality in mechanically ventilated patients with COVID-19
https://doi.org/10.1186/s13613-022-01077-7
Funding for this research was provided by:
Medical Research Scotland (CVG-1730-2020)
National Institute of Academic Anaesthesia (British Oxygen Company Chair of Anaesthesia research grant)
British Heart Foundation (RE/18/6/34217)
Chief Scientist Office, Scottish Government Health and Social Care Directorate (EP/R511705/1, EP/S030875/1)
European Union (754946-2)
Medical Research Council (MR/S018905/1)
UK Research and Innovation (MC/PC/20014)
Article History
Received: 13 July 2022
Accepted: 22 October 2022
First Online: 12 November 2022
Declarations
:
: Approval was gained from Scotland A Research Ethics Committee (REC reference 20/SS/0059). Informed consent was obtained from all participants included in the study, or their legal representative, in accordance with the Declaration of Helsinki.
: Not applicable.
: Colin Berry is employed by the University of Glasgow which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare, and Valo Health. No other competing interests declared.